Silence Therapeutics Stock Price, News & Analysis (LON:SLN)

GBX 194 -6.50 (-3.24 %)
(As of 12/15/2017 04:00 PM ET)
Previous CloseGBX 194
Today's RangeGBX 194 - GBX 194.50
52-Week RangeGBX 71.88 - GBX 254.75
Volume5,518 shs
Average Volume28,129 shs
Market Capitalization£139.61 million
P/E RatioN/A
Dividend YieldN/A

About Silence Therapeutics (LON:SLN)

Silence Therapeutics logoSilence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.

Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSGBX (0.13)
Net IncomeN/A
Net Margins-34,475.00%
Return on Equity-21.42%
Return on Assets-20.54%


Outstanding Shares69,990,000

Silence Therapeutics (LON:SLN) Frequently Asked Questions

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

Where is Silence Therapeutics' stock going? Where will Silence Therapeutics' stock price be in 2017?

2 brokerages have issued 1 year target prices for Silence Therapeutics' stock. Their predictions range from GBX 249 to GBX 276. On average, they expect Silence Therapeutics' stock price to reach GBX 262.50 in the next twelve months. View Analyst Ratings for Silence Therapeutics.

Who are some of Silence Therapeutics' key competitors?

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the folowing people:

  • Ali Mortazavi, Chief Executive Officer, Director
  • David Ellam, Chief Financial Officer, Director
  • Lars Karlsson, Head of Research and Development, Executive Director (Age 54)
  • Mark Cameron, Head of Chemistry
  • Stephen B. Parker, Independent Non-Executive Chairman of the Board (Age 57)
  • Stuart J.M. Collinson Ph.D., Non-Executive Director (Age 55)
  • Alistair William Gray, Non-Executive Director (Age 68)
  • Annalisa M. Jenkins, Non-Executive Director (Age 52)

How do I buy Silence Therapeutics stock?

Shares of Silence Therapeutics and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Silence Therapeutics' stock price today?

One share of Silence Therapeutics stock can currently be purchased for approximately GBX 194.

How big of a company is Silence Therapeutics?

Silence Therapeutics has a market capitalization of £139.61 million.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.

MarketBeat Community Rating for Silence Therapeutics (SLN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Silence Therapeutics (LON:SLN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 262.50GBX 249GBX 249GBX 249

Silence Therapeutics (LON:SLN) Consensus Price Target History

Price Target History for Silence Therapeutics (LON:SLN)

Silence Therapeutics (LON:SLN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
12/14/2017Peel HuntInitiated CoverageBuyGBX 276View Rating Details
1/9/2017Canaccord GenuityReiterated RatingBuyGBX 249View Rating Details
(Data available from 12/16/2015 forward)


Earnings History for Silence Therapeutics (LON:SLN)

No earnings announcements for this company have been tracked by


Silence Therapeutics (LON:SLN) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Silence Therapeutics (LON:SLN)

No dividend announcements for this company have been tracked by

Insider Trades

Silence Therapeutics (LON SLN) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Silence Therapeutics (LON:SLN)

Silence Therapeutics (LON SLN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Alistair GrayInsiderBuy3,848GBX 130£5,002.40
7/31/2017Andy RichardsInsiderBuy7,000GBX 147£10,290
4/18/2016Mortazavi,AliInsiderBuy160,000GBX 125£200,000
(Data available from 1/1/2013 forward)


Silence Therapeutics (LON SLN) News Headlines


SEC Filings

Silence Therapeutics (LON:SLN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.


Financials are not available for this stock.


Silence Therapeutics (LON SLN) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.